Modulating immune system development and function through microrna mir-146

a technology of immune system and microrna, which is applied in the field of immune system development and function modulation through mir146, can solve problems such as severe pathological consequences, and achieve the effect of preventing normal microrna activity

Inactive Publication Date: 2011-10-20
CALIFORNIA INST OF TECH
View PDF2 Cites 67 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0017]In some embodiments methods of increasing proliferation and / or activity of immune cells, such as B1 B cells, Marginal Zone B cells and Natural Killer cells and CD8+ T cells, are provided. In some embodiments, the methods comprise administering a miRNA-146 oligonucleotide to a target cell or target tissue, such as bone marrow. In other embodiments, the methods comprise administering a miRNA-146 expression vector to target cells or a target tissue and expressing a miRNA-146 in the target. In some embodiments, total numbers of one or more of B1 B cells, Marginal Zone B cells and Natural Killer cells and CD8+ T cells can be increased in a host by these methods.
[0018]In other embodiments, methods of decreasing proliferation and / or activity of immune cells such as B1 B cells, Marginal Zone B cells and Natural Killer cells and CD8+ T cells are provided. In some embodiments, the methods comprise administering antisense miRNA-146 oligonucleotides to target cells or a target tissue, such as bone marrow. In other embodiments, the methods comprise administering an antisense miRNA-146 expression vector to target cells or a target tissue such that antisense miRNA-146 is expressed in the target. In some embodiments, total numbers of one or more of B1 B cells, Marginal Zone B cells and Natural Killer cells and CD8+ T cells can be decreased in a host by these methods.
[0019]In other embodiments, proliferation and / or activity of immune cells such as B2 B cells and CD8αα+ T cells can be upregulated. In some embodiments, the methods comprise administering an antisense miRNA-146 oligonucleotide to target cells or a target tissue, such as bone marrow. In other embodiments, the methods comprise administering an antisense miRNA-146 expression vector to a target tissue such that antisense miRNA-146 is expressed in the target tissue. In some embodiments, total numbers of B2 B cells and / or CD8αα+ T cells can be increased in a host by these methods.

Problems solved by technology

Inflammation is a highly complex defense reaction of the host in response to an invading pathogen or injury, which when not resolved swiftly can result in quite severe pathological consequences.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modulating immune system development and function through microrna mir-146
  • Modulating immune system development and function through microrna mir-146
  • Modulating immune system development and function through microrna mir-146

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0036]miR-146 can be used to modulate immune system development and function. As a result, it can be used, for example, as a therapeutic agent to treat disease states, including those characterized by activation, particularly excessive activation of the innate immune system. Such disease states include, for example, sepsis and septic shock, neurodegeneration, neutrophilic alveolitis, asthma, hepatitis, inflammatory bowel disease, ischemia / reperfusion, septic shock, glomerulonephritis, rheumatoid arthritis, lupus, multiple sclerosis and Crohn's disease.

[0037]When miR-146a or miRNA-146b is delivered into cells of the innate immune system, among other things it dampens the production of pro-inflammatory cytokines like TNF and IL-6. Such delivery can be achieved in a variety of ways using methods well known in the art, for example, by modification of an oligonucleotide encoding a miR-146, such as a mature miR-146a or miR-146b, with cholesterol to help it easily penetrate the cell membra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
autoimmune disordersaaaaaaaaaa
sizeaaaaaaaaaa
weightaaaaaaaaaa
Login to view more

Abstract

The present disclosure relates to the finding that microRNA-146 plays a role in modulating the development and function of the immune system. Immune cell development and function can be modulated by delivery of microRNA-146 (miR-146) or antisense miR-146 to target immune cells or precursor cells. For example, in some embodiments, activity and / or proliferation of certain immune cells is regulated by administering miR-146 oligonucleotides or anti-miR-146 oligonucleotides. In other embodiments, pro-inflammatory cytokine expression in immune cells is regulated by administering a miR-146 oligonucleotide or anti-miR-146. In further embodiments, methods of regulating macrophage activity using antisense miR-146 are provided. Additional methods and compositions for regulating immune system function and development using miR-146 are disclosed.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application claims priority under 35 U.S.C. §120 as a continuation of U.S. patent application Ser. No. 12 / 337,525, filed Dec. 17, 2008, which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 61 / 007,987, filed on Dec. 17, 2007. All of the aforementioned priority applications are herein expressly incorporated by reference in their entirety.STATEMENT REGARDING FEDERALLY SPONSORED R&D[0002]The U.S. Government has certain rights in this invention pursuant to Grant No. GM039458 awarded by National Institutes of Health.REFERENCE TO SEQUENCE LISTING[0003]The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled CALTE.045C1.TXT, created Jun. 1, 2011, which is 5.2 KB in size. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION[0004]1. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A01K67/027C12N5/10C12N15/113
CPCC12N15/113C12N2310/111C12N2330/10C12N2310/141C12N2310/113
Inventor BALTIMORE, DAVIDBOLDIN, MARKTAGANOV, KONSTANTIN
Owner CALIFORNIA INST OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products